Relay Therapeutics (RLAY) Research & Development (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Research & Development data on file, last reported at $70.6 million in Q1 2026.

• On a quarterly basis, Research & Development fell 4.4% year-over-year to $70.6 million in Q1 2026; TTM through Mar 2026 was $258.1 million, a 16.86% decrease from a year earlier, with the FY2025 full-year figure at $261.4 million, down 18.08% from the prior year.
• Research & Development for Q1 2026 stood at $70.6 million, up from $55.4 million in the prior quarter.
• Over the last five years, Research & Development for RLAY reached as high as $92.0 million in Q2 2024 and fell as low as $51.7 million in Q1 2022.
• Historically, Research & Development has averaged $72.2 million across 5 years, with a median of $70.6 million in 2026.
• Across the five-year window, Research & Development surged 68.73% in 2022 and tumbled 30.54% in 2025, its largest moves.
• Year by year, Research & Development stood at $67.3 million in 2022, then increased by 15.19% to $77.5 million in 2023, then fell by 12.16% to $68.1 million in 2024, then decreased by 18.6% to $55.4 million in 2025, then rose by 27.34% to $70.6 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $70.6 million in Q1 2026, $55.4 million in Q4 2025, and $68.3 million in Q3 2025.